Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real‐world evidence

Figures

• 

  Figure 1. Effect of hypertriglyceridaemia on risk, outcomes, healthcare utilization and costs.41, 44, 45, 47, 50 A, Estimated number of atherosclerotic cardiovascular disease (ASCVD) events in 10 years among people aged 40–79 years, by triglyceride (TG) concentration, and stratified by statin use, based on the 9593 participants identified in the National Health and Nutrition Examination Survey (NHANES) database. The estimated number of events in 10 years was calculated by multiplying the estimated ASCVD risk score by the corresponding projected population (the estimated ASCVD risk score also indicated the proportion of events expected to occur in 10 years). The 10‐year risk of ASCVD was defined as non‐fatal myocardial infarction (MI) or coronary heart disease death, or fatal or non‐fatal stroke, over a 10‐year period among people free from ASCVD at the beginning of the period. B, Increase in risk in patients with TG levels ≥1.69 mmol/L and in the subcohort with TG levels 2.26–5.64 mmol/L versus comparators from the Optum Research Database. See Table 2 for analysis details. C, Increase in risk in patients from the Kaiser Permanente database with TG levels 2.26–5.64 mmol/L versus patients…